Protara Initiates Phase 3 Trial for IV Choline Chloride to Address Choline Deficiency in Long-Term Parenteral Support Patients.

Protara Therapeutics has dosed the first patient in its Phase 3 THRIVE-3 trial for IV Choline Chloride to treat choline deficiency in patients on long-term parenteral support. The trial aims to establish IV choline as the first FDA-approved therapy for this underserved population. Interim analysis is expected in H2 2026. The stock has traded between $2.77 and $7.82 over the past year and is currently at $5.46, up 6.42%.